secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001396814-24-000140
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance
--------------------------------------------------------------------------------

- Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.
- GAAP net loss $143.5M ($3.11/sh) on $163.2M goodwill impairment; non-GAAP net income $38.2M.
- Adjusted EBITDA $54.7M; cash $453.8M. FY 2024 guidance reaffirmed ($680M-$705M rev).
- CMS final rule confirms separate NOPAIN reimbursement for EXPAREL/iovera° starting Jan 1, 2025; new J-code J0666 effective same date.
- Executive employment agreements amended for Gaugler, Slonin, Williams: enhanced severance (12-mo salary continuation; 18-mo on change of control).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000140/0001396814-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000140/pcrx-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer